Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jul 6 · below the Ichimoku cloud · RSI 43 · MACD above its signal
| 1.84 | 52-week high | +100.00% |
| 1.49 | Previous month high | +61.96% |
| 1.01 | R3 (classic) | +10.14% |
| 0.9867 | R2 (classic) | +7.25% |
| 0.9600 | Previous day high | +4.35% |
| 0.9533 | R1 (classic) | +3.62% |
| 0.9267 | Pivot | +0.72% |
| 0.9200 | Price now | |
| 0.9150 | Previous week high | −0.54% |
| 0.9010 | Previous month low | −2.07% |
| 0.9000 | Previous day low | −2.17% |
| 0.8933 | S1 (classic) | −2.90% |
| 0.8667 | S2 (classic) | −5.80% |
| 0.8333 | S3 (classic) | −9.42% |
| 0.8210 | Previous week low | −10.76% |
| 0.7690 | 52-week low | −16.41% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $427.6K | 0.00% | 331.51K | +45% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ALLR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 27, 2026 | Mclaughlin Gerald WDirector | Stock Award(Grant) at price 0.00 per share. | 45K | — |
| Jan 27, 2026 | Jensen ThomasChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 200K | — |
| Jan 27, 2026 | Graff Jeremy R.President | Stock Award(Grant) at price 0.00 per share. | 133.3K | — |
| Jan 27, 2026 | Ervin Jeffrey S.Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 150K | — |
| Jan 6, 2026 | Hoeiland JesperDirector | Stock Award(Grant) at price 0.00 per share. | 25K | — |
| Jan 6, 2026 | Graff Jeremy R.President | Stock Award(Grant) at price 0.00 per share. | 133.3K | — |
| Sep 29, 2025 | Graff Jeremy R.President | — | 39.5K | — |
| Jan 21, 2025 | Jensen ThomasChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 396.7K | — |
| Jan 21, 2025 | Graff Jeremy R.Officer | Stock Award(Grant) at price 0.00 per share. | 144.4K | — |
| Jan 21, 2025 | Epshinsky AlexanderChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 29.5K | — |
TimeframesUp on the hourly, down on the daily and weekly, mixed on the monthly.
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.4 | -3.0 | 12.4 | 23.9 | 21.5 | -21.3 | -6.2 | 16.5 | -25.5 | -12.4 | −14.8% | ||
| 2025 | -4.3 | -28.7 | 17.3 | 28.1 | -27.8 | 16.5 | 3.0 | 48.1 | 2.6 | -8.2 | -8.3 | -18.8 | −7.7% |
| 2024 | -21.1 | -11.0 | -22.2 | -78.9 | -51.5 | -65.4 | -14.6 | 0.0 | -61.4 | -33.6 | -21.4 | 6.4 | −99.6% |
| 2023 | -15.0 | -26.0 | -74.1 | -73.8 | -40.0 | -37.5 | -61.5 | -27.2 | -59.6 | -25.4 | -0.7 | -0.4 | −99.9% |
| 2022 | -21.3 | -48.2 | -51.8 | -24.0 | 82.6 | -53.4 | -9.1 | -2.5 | -6.0 | -49.1 | -19.8 | -34.5 | −97.2% |
| 2021 | — |
Buy / hold / sell counts
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.